Preliminary results of a randomized, double blind, placebo controlled trial on osteoarthritis of the knee using ActiPatch Therapy have been announced.
BioElectronics Corporation says the initial interim analysis showed statistically significant results for the primary and secondary outcomes measures. The study is being led by Doctor Gianluca Bagnato, Division of Rheumatology, University Hospital Gaetano Martino, Messina, Italy. The final analysis of the full study data set will be carried out soon and the results have been accepted in the Annals of the Rheumatic Diseases and presented at the European League against Rheumatism 2014 conference.
"The completion of these randomized, placebo controlled trials, on pain resulting from three very distinct musculoskeletal pathophysiological processes, is highly significant," commented Andrew Whelan, BioElectronics CEO. "The data from these high quality clinical trials will be available before the FDA's May 21st deadline for comments on proposed reclassification of our devices to Class II. This schedule will allow us to submit the 510K application without any delay once the final ruling is made by the FDA."
BioElectronics is conducting a series of clinical research studies using its medical devices for other musculoskeletal pain conditions that include, acute nonspecific lower back pain, as well as the surgical indications of postoperative recovery for 3rd molar extraction and hernia repair.
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- What Do EU Countries Give Up When They Opt-out Of GMO Crops? And For Whom?
- An Easy Problem
- Nobel Prize Validates Chinese Medicine? Nope.
- Thank You Guido
- Mother Jones Hates Scientists - And Their Bias Shows
- Machine learning vs NRA, a Grand Challenge
- September 24th, 2015 - Just Another Day In Space - Asteroid Flybys, "Blood Moons" And Armageddon Demystified
- "This is a bit of irony: Mother Jones, which can never be bothered with facts or truth and got sued..."
- "Great piece Steve. While the potential for suffering and death in Africa especially thanks to this..."
- "I look forward to more threats and libel from you in the very near future. It's your stock in trade..."
- "Dear Mr. Campbell: Again you spin and dissemble. It was quite clear from the many tweets between..."
- "One of us does not know what libel means (hint: It is you). Calling me a felon and a fraud is libel..."
- FDA-Approved Test for Meningitis is a Home Run
- Trends In Smoking – Chinese Men In Peril, American Women Get Better Cessation
- Counter-Point: Activists Operate By Outrage, Not Fear
- Whole Foods Recalls Organic Roquefort Cheeses After Listeria Found
- Suicide Tries Linked to Weight-Loss Surgery? Study Doesn’t Show
- Following Rules, Refreezing Thawed Meat is Safe
- Beetles provide clues about the genetic foundations of parenthood
- Trees to power: McMaster engineers build better energy storage device
- High dose chemo & stem cell transplantation results in long-term survival for amyloid patients
- 'Blind analysis' could reduce bias in social sciences papers
- Adoption of streamlined breast cancer treatment has stagnated, study finds